Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study

Leukemia Research

Volumn 36, Issue 10, 2012, Pages 1229-1236

  Ogata, Kiyoyuki ^a   Kakumoto, Keiji ^b   Matsuda, Akira ^c   Tohyama, Kaoru ^d   Tamura, Hideto ^a   Ueda, Yasunori ^e   Kurokawa, Mineo ^f   Takeuchi, Jin ^g   Shibayama, Hirohiko ^h   Emi, Nobuhiko ⁱ   Motoji, Toshiko ^j   Miyazaki, Yoshihide ^b   Tamaki, Hiroya ^k   Mitani, Kinuko ^l   Naoe, Tomoki ^m   Sugiyama, Haruo ^h   Takaku, Fumimaro ⁿ  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e KURASHIKI CENTRAL HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^k HYOGO COLLEGE OF MEDICINE   (Japan)

^l DOKKYO MEDICAL UNIVERSITY   (Japan)

^m NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ JICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

B7 H1; CD7; Disease progression; Flow cytometry; Myeloblasts; Myelodysplastic syndromes

Indexed keywords

CD15 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1;

ACUTE LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD34 SELECTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; VALIDATION STUDY;

AGED; ANTIGENS, CD274; ANTIGENS, CD7; BLAST CRISIS; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR CELLS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84865179308     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.006     Document Type: Article

References (36)

1. Cazzola M., Della Porta M.G., Travaglino E., Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011, 38:627-634.
2. Stetler-Stevenson M., Arthur D.C., Jabbour N., Xie X.Y., Molldrem J., Barrett A.J., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001, 98:979-987.
3. Ogata K., Nakamura K., Yokose N., Tamura H., Tachibana M., Taniguchi O., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002, 100:3887-3896.
4. Kussick S.J., Wood B.L. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003, 127:1140-1147.
5. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102:394-403.
6. Malcovati L., Della Porta M.G., Lunghi M., Pascutto C., Vanelli L., Travaglino E., et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005, 19:776-783.
7. Della Porta M.G., Malcovati L., Invernizzi R., Travaglino E., Pascutto C., Maffioli M., et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006, 20:549-555.
8. Ogata K., Kishikawa Y., Satoh C., Tamura H., Dan K., Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006, 108:1037-1044.
9. van de Loosdrecht A.A., Westers T.M., Westra A.H., Drager A.M., van der Velden V.H., Ossenkoppele G.J. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008, 111:1067-1077.
10. Kern W., Haferlach C., Schnittger S., Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010, 116:4549-4563.
11. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
12. Loken M.R., van de Loosdrecht A., Ogata K., Orfao A., Wells D.A. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008, 32:5-17.
13. van de Loosdrecht A.A., Alhan C., Bene M.C., Della Porta M.G., Drager A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNET working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94:1124-1134.
14. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European Leukemia Net working group. Leukemia; doi:10.1038/leu.2012.30.
15. Kondo A., Yamashita T., Tamura H., Zhao W., Tsuji T., Shimizu M., et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010, 116:1124-1131.
16. Satoh C., Tamura H., Yamashita T., Tsuji T., Dan K., Ogata K. Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. Leuk Res 2009, 33:326-331.
17. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
18. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. [erratum appears in Blood 1998 Feb 1;91(3):1100].
19. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin Oncol 2007, 25:3503-3510.
20. Satoh C., Dan K., Yamashita T., Jo R., Tamura H., Ogata K. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 2008, 32:699-707.
21. Ogata K., Della Porta M.G., Malcovati L., Picone C., Yokose N., Matsuda A., et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009, 94:1066-1074.
22. Della Porta M.G., Picone C., Pascutto C., Malcovati L., Tamura H., Handa H., et al. Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 2012, 97. 10.3324/haemat2011.048421.
23. Hunziker S., Bivens M.J., Cocchi M.N., Miller J., Salciccioli J., Howell M.D., et al. International validation of the out-of-hospital cardiac arrest score in the United States. Crit Care Med 2011, 39:1670-1674.
24. Wadelius M., Chen L.Y., Lindh J.D., Eriksson N., Ghori M.J., Bumpstead S., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
25. Sternberg A., Killick S., Littlewood T., Hatton C., Peniket A., Seidl T., et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005, 106:2982-2991.
26. Loken M.R., Wells D.A. Normal antigen expression in hematopoiesis: basis for interpreting leukemia phenotypes. Immunophenotyping 2000, 133. Wiley-Liss, New York. C.C. Stewart, J.K.A. Nicholson (Eds.).
27. Chabannon C., Wood P., Torok S.B. Expression of CD7 on normal human myeloid progenitors. J Immunol 1992, 149:2110-2113.
28. Tjonnfjord G.E., Veiby O.P., Steen R., Egeland T. T lymphocyte differentiation in vitro from adult human prethymic CD34+ bone marrow cells. J Exp Med 1993, 177:1531-1539.
29. Tien H.F., Wang C.H. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma 1998, 31:93-98.
30. Lo Coco F., De Rossi G., Pasqualetti D., Lopez M., Diverio D., Latagliata R., et al. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. Br J Haematol 1989, 73:480-485.
31. Ogata K., Yokose N., Shioi Y., Ishida Y., Tomiyama J., Hamaguchi H., et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001, 115:612-615.
32. Yong A.S., Szydlo R.M., Goldman J.M., Apperley J.F., Melo J.V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006, 107:205-212.
33. Kosugi N., Ebihara Y., Nakahata T., Saisho H., Asano S., Tojo A. CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia. Clin Cancer Res 2005, 11:505-511.
34. Tamura H., Dong H., Zhu G., Sica G.L., Flies D.B., Tamada K., et al. B7-H1 co stimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001, 97:1809-1816.
35. Tamura H., Ogata K., Dong H., Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol. 2003, 78:321-328.
36. Ishibashi M., Tamura H., Ogata K. Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment. Leuk Res 2011, 35:1449-1452.